应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
AZN 阿斯利康
休市中 08-14 16:00:00 EDT
156.45
-0.79
-0.50%
盘后
156.02
-0.43
-0.27%
19:58 EDT
最高
156.46
最低
154.53
成交量
369.79万
今开
155.50
昨收
157.24
日振幅
1.23%
总市值
2,427亿
流通市值
2,345亿
总股本
15.51亿
成交额
5.76亿
换手率
0.25%
流通股本
14.99亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
市场消息：英国首相顾问就布里斯托尔并购案联系阿斯利康。
智通财经 · 08-13
市场消息：英国首相顾问就布里斯托尔并购案联系阿斯利康。
第一三共/阿斯利康(AZN.US)重磅ADC药物“德曲妥珠单抗”又一项新适应症在中国获批上市
智通财经 · 08-13
第一三共/阿斯利康(AZN.US)重磅ADC药物“德曲妥珠单抗”又一项新适应症在中国获批上市
石药创新(300765.SZ)：巨石生物已收到阿斯利康支付的3000万美元首付款
智通财经 · 08-12
石药创新(300765.SZ)：巨石生物已收到阿斯利康支付的3000万美元首付款
石药创新：控股子公司收到阿斯利康3000万美元首付款
智通财经 · 08-12
石药创新：控股子公司收到阿斯利康3000万美元首付款
礼来上半年替尔泊肽大卖277亿美元；石药集团与阿斯利康成立合资公司丨医药早参
每日经济新闻 · 08-06
礼来上半年替尔泊肽大卖277亿美元；石药集团与阿斯利康成立合资公司丨医药早参
美股异动｜阿斯利康反弹涨超4%，消息人士否认与施贵宝合并传闻
格隆汇 · 08-05
美股异动｜阿斯利康反弹涨超4%，消息人士否认与施贵宝合并传闻
异动解读｜阿斯利康盘中上涨4.97%，合并施贵宝传闻遭权威否认后超跌修复
行情直击 · 08-05
异动解读｜阿斯利康盘中上涨4.97%，合并施贵宝传闻遭权威否认后超跌修复
石药集团：收到阿斯利康就战略研发合作协议项下的1000万美元里程碑付款
智通财经 · 08-05
石药集团：收到阿斯利康就战略研发合作协议项下的1000万美元里程碑付款
阿斯利康股价大涨，消息称目前未与百时美施贵宝进行并购谈判后，该股日内涨幅现已达到3.5%。
智通财经 · 08-05
阿斯利康股价大涨，消息称目前未与百时美施贵宝进行并购谈判后，该股日内涨幅现已达到3.5%。
市场消息：阿斯利康与施贵宝之间没有就潜在交易进行任何讨论
老虎资讯综合 · 08-05
市场消息：阿斯利康与施贵宝之间没有就潜在交易进行任何讨论
异动解读｜阿斯利康盘前上涨4.77%，合并施贵宝传闻遭多方泼冷水后股价修复
行情直击 · 08-05
异动解读｜阿斯利康盘前上涨4.77%，合并施贵宝传闻遭多方泼冷水后股价修复
消息人士表示，阿斯利康(AZN.US)与施贵宝(BMY.US)之间没有就潜在交易进行任何讨论。
智通财经 · 08-05
消息人士表示，阿斯利康(AZN.US)与施贵宝(BMY.US)之间没有就潜在交易进行任何讨论。
一位知情资深消息人士称，阿斯利康与百时美施贵宝“从始至终从未有过交易谈判”。
智通财经 · 08-05
一位知情资深消息人士称，阿斯利康与百时美施贵宝“从始至终从未有过交易谈判”。
石药集团：与阿斯利康就成立合资公司签署合资合同。
智通财经 · 08-05
石药集团：与阿斯利康就成立合资公司签署合资合同。
阿斯利康拟与百时美施贵宝4000亿美元重组传闻背后：专利悬崖、产品短板倒逼，AZ端反对声大
蓝鲸财经 · 08-04
阿斯利康拟与百时美施贵宝4000亿美元重组传闻背后：专利悬崖、产品短板倒逼，AZ端反对声大
美银：阿斯利康并购施贵宝逻辑存疑，监管与协同效应成焦点
老虎资讯综合 · 08-04
美银：阿斯利康并购施贵宝逻辑存疑，监管与协同效应成焦点
RBC泼冷水：阿斯利康(AZN.US)收购百时美施贵宝(BMY.US)“可能性极低”，估值分歧与反垄断成最大拦路虎
智通财经 · 08-04
RBC泼冷水：阿斯利康(AZN.US)收购百时美施贵宝(BMY.US)“可能性极低”，估值分歧与反垄断成最大拦路虎
阿斯利康宣布创新药英卓凡正式在中国上市
南方财经网 · 08-04
阿斯利康宣布创新药英卓凡正式在中国上市
阿斯利康投资者对巨型并购谈判表达担忧。
智通财经 · 08-04
阿斯利康投资者对巨型并购谈判表达担忧。
阿斯利康伦敦股价收跌9%，创2020年3月份以来最大单日跌幅。
智通财经 · 08-03
阿斯利康伦敦股价收跌9%，创2020年3月份以来最大单日跌幅。
加载更多
公司概况
公司名称：
阿斯利康
所属市场：
NYSE
上市日期：
--
主营业务：
阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。
发行价格：
--
{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":156.45,"timestamp":1786737600000,"preClose":157.24,"halted":0,"volume":3697879,"hourTrading":{"tag":"盘后","latestPrice":156.0249,"preClose":156.45,"latestTime":"19:58 EDT","volume":35279,"amount":5519296.9453,"timestamp":1786751936806,"change":-0.4251,"changeRate":-0.002717,"amplitude":0.002717},"delay":0,"changeRate":-0.005024166878656961,"floatShares":1498932637,"shares":1551000000,"eps":6.679974,"marketStatus":"休市中","change":-0.79,"latestTime":"08-14 16:00:00 EDT","open":155.5,"high":156.46,"low":154.53,"amount":575942842.28929,"amplitude":0.012274,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.679974,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":7,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NYSE","adjPreClose":157.24,"dividendRate":0.020201,"preHourTrading":{"tag":"盘前","latestPrice":155.5,"preClose":157.24,"latestTime":"09:29 EDT","volume":32159,"amount":5015489.98326,"timestamp":1786714192855,"change":-1.74,"changeRate":-0.011066,"amplitude":0.015263},"postHourTrading":{"tag":"盘后","latestPrice":156.0249,"preClose":156.45,"latestTime":"19:58 EDT","volume":35279,"amount":5519296.9453,"timestamp":1786751936806,"change":-0.4251,"changeRate":-0.002717,"amplitude":0.002717},"volumeRatio":1.029474575705481,"impliedVol":0.2667,"impliedVolPercentile":0.3267},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2659165315","title":"市场消息：英国首相顾问就布里斯托尔并购案联系阿斯利康。","url":"https://stock-news.laohu8.com/highlight/detail?id=2659165315","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659165315?lang=zh_cn&edition=full","pubTime":"2026-08-13 23:13","pubTimestamp":1786633991,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1829250122.USD","LU0109394709.USD","LU0058720904.USD","LU2237443622.USD","LU2237443895.HKD","LU2468319806.SGD","BK4588","LU0889565916.HKD","LU2462157665.USD","AZNH","LU2417539215.USD","LU0289739699.SGD","LU0320765992.SGD","LU2237443382.USD","LU0432979614.USD","LU0310800379.SGD","IE00B3T34201.USD","LU2237443465.HKD","LU2236285917.USD","BK4568","AZN","LU0128525929.USD","LU0708994859.HKD","LU1267930573.SGD","LU2456880835.USD","BK4007","LU2237443978.SGD","BK4585","LU2089984988.USD","LU0029864427.USD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659860121","title":"第一三共/阿斯利康(AZN.US)重磅ADC药物“德曲妥珠单抗”又一项新适应症在中国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2659860121","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659860121?lang=zh_cn&edition=full","pubTime":"2026-08-13 07:21","pubTimestamp":1786576889,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月12日，第一三共宣布，其与阿斯利康合作开发的重磅ADC药物“德曲妥珠单抗”一项新适应症获批上市，适应症为联合帕妥珠单抗用于不可切除或转移性HER2阳性成人乳腺癌患者的一线治疗。德曲妥珠单抗(DS-8201，商品名：优赫得®/Enhertu)是一款靶向HER2的ADC药物，由第一三共开发，并与阿斯利康在全球范围内共同开发和商业化。该药由HER2靶向抗体、可裂解四肽连接子和拓扑异构酶I抑制剂DXd(依喜替康衍生物)组成，DAR约为8。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479235.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0310800379.SGD","LU2237443895.HKD","LU1829250122.USD","LU0289739699.SGD","IE00B3T34201.USD","LU2456880835.USD","BK4585","LU0889565916.HKD","LU0029864427.USD","BK4080","LU0432979614.USD","BK4007","LU0708994859.HKD","LU0320765992.SGD","LU2237443382.USD","NETL","LU1267930573.SGD","BK4588","LU2236285917.USD","LU0058720904.USD","BK4231","LU0128525929.USD","LU0109394709.USD","LU2237443622.USD","LU2417539215.USD","LU2237443465.HKD","AZNH","IPOS","LU2468319806.SGD","LU2237443978.SGD","LU2089984988.USD","BK4568","AZN","LU2237443549.SGD","ADC","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658769979","title":"石药创新(300765.SZ)：巨石生物已收到阿斯利康支付的3000万美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2658769979","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658769979?lang=zh_cn&edition=full","pubTime":"2026-08-12 18:52","pubTimestamp":1786531939,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药创新(300765.SZ)发布公告，2026年7月1日，公司控股子公司巨石生物与阿斯利康签署《合作、选择权及授权协议》，将与阿斯利康在新型小干扰核酸候选药物领域开展战略合作，开发新型肝外递送小干扰分子核酸候选药物。根据协议约定，巨石生物已于2026年8月12日收到阿斯利康支付的3000万美元首付款(实际到账金额须扣除银行手续费)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4568","LU0029864427.USD","LU1829250122.USD","300765","LU0310800379.SGD","LU2417539215.USD","LU2237443978.SGD","LU2237443465.HKD","BK4585","LU0708994859.HKD","LU0058720904.USD","IE00B3T34201.USD","LU2468319806.SGD","LU0432979614.USD","BK4588","LU0320765992.SGD","LU2237443549.SGD","LU2462157665.USD","LU2456880835.USD","LU2237443382.USD","LU2236285917.USD","LU2237443895.HKD","LU0889565916.HKD","LU0289739699.SGD","LU0109394709.USD","BK0226","AZN","LU2089984988.USD","AZNH","LU0128525929.USD","LU1267930573.SGD","BK4007","LU2237443622.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658811976","title":"石药创新：控股子公司收到阿斯利康3000万美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2658811976","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658811976?lang=zh_cn&edition=full","pubTime":"2026-08-12 18:06","pubTimestamp":1786529180,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2237443549.SGD","LU0128525929.USD","LU2468319806.SGD","LU0432979614.USD","AZNH","LU2237443895.HKD","LU0109394709.USD","LU2236285917.USD","LU1267930573.SGD","LU2237443622.USD","LU2417539215.USD","LU2089984988.USD","LU2462157665.USD","LU2237443382.USD","LU2456880835.USD","LU2237443978.SGD","LU0320765992.SGD","LU2237443465.HKD","LU0058720904.USD","LU0310800379.SGD","LU0889565916.HKD","BK4568","BK4588","IE00B3T34201.USD","BK4585","BK4007","AZN","LU0708994859.HKD","LU0029864427.USD","LU0289739699.SGD","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657726255","title":"礼来上半年替尔泊肽大卖277亿美元；石药集团与阿斯利康成立合资公司丨医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2657726255","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657726255?lang=zh_cn&edition=full","pubTime":"2026-08-06 07:00","pubTimestamp":1785970805,"startTime":"0","endTime":"0","summary":"丨2026年8月6日星期四丨NO.1礼来：上半年替尔泊肽大卖277亿美元，中国区收入增长73%8月5日，礼来披露半年度业绩，公司上半年实现总营收427.73亿美元，同比增长49%。从地区分布来看，上半年美国市场收入265.32亿美元，同比增长37%，中国市场收入16.35亿美元，同比增长73%。上半年，礼来8款核心产品合计收入290.77亿美元，占总营收68%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608063832986566.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608063832986566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2456880835.USD","SG9999018857.SGD","JDOC","LU2491050071.SGD","LU0471298777.SGD","LU2491050154.USD","IE00BK4W5L77.USD","LU0823434583.USD","LU0029864427.USD","688331","LU1008478684.HKD","LU2237443622.USD","IE0002141913.USD","IE0008369823.USD","LU2602419157.SGD","SG9999017495.SGD","LU0708995401.HKD","BK4585","LU1629891620.HKD","LU0315179316.USD","LU2360106947.USD","IE0004445015.USD","BK1574","LLY","AZN","LU0820561818.USD","LU0882574055.USD","IE00B775H168.HKD","LU1720051017.SGD","LU0501845795.SGD","FHLC","LU1152091754.HKD","LU2750360997.AUD","LLYX","LU1623119135.USD","LU0466842654.USD","LU1145028129.USD","LU0266013472.USD","LU2089283258.USD","LU1323610961.USD","LU0964807845.USD","IE00B2B36J28.USD","SGXZ81514606.USD","IE00BJJMRX11.SGD","LU0210536198.USD","IE0001KFT4U8.USD","LU1868836757.USD","MHIP","LU2896262040.SGD","LU2106854487.HKD","TMED","BK1191","LU2023250330.USD","LU1267930730.SGD","LU2264538146.SGD","THNR","IE00BKPKM429.USD","IE00BFTCPJ56.SGD","LU0588546209.SGD","IE00BK4W5M84.HKD","SG9999014898.SGD","IE00BJJMRY28.SGD","SG9999013999.USD","LU1328277881.USD","LU2361045086.USD","BK4534","LU0114720955.EUR","LU1303224171.USD","LU2039709279.SGD","LU0354030511.USD","MEDI","IYH","LU2063271972.USD","MEDX","IE00B543WZ88.USD","LU0067412154.USD","LU1366192091.USD","BK4516","SGXZ51526630.SGD","FTXH","LU1226288170.HKD","LU0880133367.SGD","SG9999015945.SGD","LU1868836591.USD","BK1515","LU1969619763.USD","LU0345770993.USD","IE00BFSS7M15.SGD","BK1588","LU2023251221.USD","LU2237443382.USD","IE00BZ08YT58.USD","LU0320765992.SGD","SG9999014914.USD","SGXZ57979304.SGD","LU0140636845.USD","LU2237443465.HKD","LU2361044949.HKD","LU2111349929.HKD","LU1814569148.SGD","LU1807302812.USD","IE0009355771.USD","LU1035775433.USD","LU2357305700.SGD","BK4599","VHT","LU0708994859.HKD","LU2471134952.CNY","LU0323591593.USD","LU0256863902.USD","LU2461242641.AUD","LU1152091168.USD","LU1804176565.USD","LU0289739699.SGD","IE00BZ08YR35.GBP","IE00B031HY20.USD","SG9999014906.USD","IE00BN29S564.USD","LU0158827948.USD","BK1161","LU0787776722.HKD","LU0640476718.USD","LU1069344957.HKD","LU0094547139.USD","HK0000165453.HKD","ILDR","BK4568","BK1521","LU2271345857.HKD","LU2462591350.SGD","LU2237438978.USD","BK1500","LU2746668974.SGD","CURE","LU0256863811.USD","LU0122379950.USD","LU1267930573.SGD","XLV","LU1226288253.USD","SG9999015978.USD","LU0225283273.USD","LU1989771016.USD","LU1093756168.USD","LU1960683339.HKD","IE00BJJMRZ35.SGD","LU2328871848.SGD","GDOC","SGXZ99366536.SGD","LU2468319806.SGD","LU0823416689.USD","LU0823434740.USD","LU1993786604.SGD","LU1251922891.USD","LU0471298694.HKD","LU2112291526.USD","OZEM","LU0672654240.SGD","LU0320765059.SGD","IE0008368742.USD","SG9999004220.SGD","WDNA","SG9999001176.SGD","LU2168564149.EUR","LU1232071149.USD","LU1770034418.SGD","LU2023250504.SGD","IE0004445239.USD","LU1226287875.USD","IE00BZ08YS42.EUR","LU0079474960.USD","LU1057294990.SGD","TRUH","LU2089984988.USD","LU1974910355.USD","LU2471134523.USD","LU1868837136.USD","SG9999001176.USD","LU1813983027.USD","KURE","BK4007","LU1280957306.USD","BK4581","HRTS","LU2089284900.SGD","BK1583","LU0326950275.SGD","IE00B4JS1V06.HKD","LU0943347566.SGD","IXJ","LLII","LU2028103732.USD","LU2491049909.HKD","LU0820562030.AUD","LU0307460666.USD","BK4533","IE00B7KXQ091.USD","LU0238689110.USD","LU1829250122.USD","LU0072913022.USD","LU2168564065.EUR","IE00B1XK9C88.USD","LU0158827781.USD","LU0198837287.USD","LU0316494557.USD","LU0097036916.USD","LU0354030438.USD","LU0353189680.USD","LU0061475181.USD","01093","LU2265009873.SGD","LU1127390331.HKD","LU0203202063.USD","LU1093756325.SGD","09995","IE0005OL40V9.USD","LU0786609619.USD","LU2237443549.SGD","ELIS","LU2471134796.USD","LU2746668461.USD","LU0820561909.HKD","LU2552382215.SGD","LU2168563687.JPY","LU2168564222.USD","LU1868836914.USD","LU2087625088.SGD","06160","LU0314109678.HKD","IE00B3T34201.USD","LU0432979614.USD","LU1979441026.SGD","LLYZ","LU1291159041.SGD","LU1917777945.USD","LU0106261372.USD","LU1064131342.USD","LU0889565916.HKD","LU0109394709.USD","LU0203201768.USD","LU0310800379.SGD","688235","SG9999015986.USD","LU0456855351.SGD","LU0128525929.USD","IE00BJT1NW94.SGD","PPH","LU1868837300.USD","LU2417539215.USD","ELIL","LU1551013342.USD","LU2213496289.HKD","LU2211815571.USD","LU0683600562.USD","LU1548497426.USD","IE00BKDWB100.SGD","LU0345770308.USD","IE00B4R5TH58.HKD","IHE","LU2108987350.USD","LU0385154629.USD","LU2237443895.HKD","ONC","IE00B5MMRT66.SGD","LU1226287529.USD","IE00BJLML261.HKD","LU2552382132.HKD","LU2756315318.SGD","LU2756315664.SGD","SG9999018865.SGD","LU1712237335.SGD","LU2236285917.USD","CANC","LU1951186391.HKD","LU2552382058.USD","LU2237443978.SGD","AZNH","LU0133085943.USD","LU1061106388.HKD","SG9999014880.SGD","LU0174119429.USD","IE00BFSS8Q28.SGD","BK4588","LU2361044865.SGD","LU0006306889.USD","LU1720051108.HKD","LU0234572021.USD","LU0689472784.USD","LU1719994722.HKD","LU1023059063.AUD","LU1226287792.SGD","SG9999015952.SGD","LU2324357040.USD","LU2750360641.GBP","LU1551013425.SGD","LU0882574139.USD","SGXZ31699556.SGD","GB00BDT5M118.USD","LU0096364046.USD","AGNG","RXL","LU0353189763.USD","LU0109391861.USD","IE00BWXC8680.SGD","LU2168564495.EUR","LU0417517546.SGD","LU1983299246.USD","LU2462157665.USD","LU2471134879.HKD","LU1988902786.USD","LU0058720904.USD","IE00B1BXHZ80.USD","PJP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657540291","title":"美股异动｜阿斯利康反弹涨超4%，消息人士否认与施贵宝合并传闻","url":"https://stock-news.laohu8.com/highlight/detail?id=2657540291","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657540291?lang=zh_cn&edition=full","pubTime":"2026-08-05 21:46","pubTimestamp":1785937567,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1267930573.SGD","BMY","IE00BJT1NW94.SGD","BK4581","AZN","BK4559","LU1291159041.SGD","LU0882574055.USD","LU0267386448.USD","LU1718418525.SGD","LU2242652126.USD","LU2242646821.SGD","FTXH","LU0237698245.USD","LU0029864427.USD","LU1585245621.USD","LU1670711040.USD","LU1430594728.SGD","LU0289739699.SGD","LU0320765992.SGD","LU1829250122.USD","LU1868836591.USD","LU0456855351.SGD","LU2236285917.USD","BK4568","LU2133065610.SGD","LU0058720904.USD","LU2237443622.USD","LU2125154935.USD","LU1868836914.USD","IHE","LU1983299246.USD","LU0096364046.USD","LU0306806265.USD","IE00BFXG1179.USD","IE0009355771.USD","LU1868837136.USD","IE00BSNM7G36.USD","LU1093756325.SGD","BK4532","LU1093756168.USD","LU0114720955.EUR","IE00BFTCPJ56.SGD","BK4585","LU0889565916.HKD","LU0985481810.HKD","LU2237443549.SGD","LU2462157665.USD","LU1989771016.USD","AZNH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154589729","title":"异动解读｜阿斯利康盘中上涨4.97%，合并施贵宝传闻遭权威否认后超跌修复","url":"https://stock-news.laohu8.com/highlight/detail?id=1154589729","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154589729?lang=zh_cn&edition=full","pubTime":"2026-08-05 21:38","pubTimestamp":1785937112,"startTime":"0","endTime":"0","summary":"8月5日，阿斯利康盘中上涨4.97%，报163.17美元/股，成交额3.48亿美元。消息面上，多位知情资深消息人士明确表示，阿斯利康与百时美施贵宝之间\"从始至终从未有过交易谈判\"，此前合并传闻被正式否认。此外，石药集团宣布与阿斯利康签署合资合同并收到1000万美元里程碑付款，业务拓展信号积极。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康盘中上涨4.97%，合并施贵宝传闻遭权威否认后超跌修复","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657547492","title":"石药集团：收到阿斯利康就战略研发合作协议项下的1000万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2657547492","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657547492?lang=zh_cn&edition=full","pubTime":"2026-08-05 21:12","pubTimestamp":1785935534,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2468319806.SGD","BK4585","LU0029864427.USD","AZNH","IE00B3T34201.USD","LU2237443622.USD","LU0128525929.USD","LU2456880835.USD","LU0058720904.USD","AZN","LU2237443382.USD","LU2417539215.USD","LU0889565916.HKD","LU2237443978.SGD","LU0432979614.USD","LU1829250122.USD","LU2237443465.HKD","LU2089984988.USD","LU2462157665.USD","LU2237443549.SGD","BK4588","LU1267930573.SGD","LU0289739699.SGD","LU0109394709.USD","LU2236285917.USD","LU2237443895.HKD","BK4007","BK4568","LU0708994859.HKD","LU0310800379.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657542821","title":"阿斯利康股价大涨，消息称目前未与百时美施贵宝进行并购谈判后，该股日内涨幅现已达到3.5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657542821","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657542821?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:32","pubTimestamp":1785933172,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0058720904.USD","LU0306807586.USD","LU1829250122.USD","LU2596442595.SGD","LU2237443978.SGD","LU0128525929.USD","LU0114720955.EUR","LU1868836591.USD","LU0061475181.USD","IE0002141913.USD","LU0889565916.HKD","BMY","CALF","IE00B3T34201.USD","LU1430594728.SGD","LU2242652126.USD","LU1670710661.SGD","LU0321505439.SGD","LU0267386448.USD","LU0029864427.USD","LU1093756325.SGD","IE00BJJMRZ35.SGD","LU1868836914.USD","LU1261432733.SGD","LU0882574055.USD","BK4007","AZNH","AZN","LU1868837136.USD","LU2468319806.SGD","BK4585","LU2242646821.SGD","LU1093756168.USD","LU2456880835.USD","XMMO","FTXH","IHE","MYLD","IE0009355771.USD","LU0310800379.SGD","LU0868494617.USD","IE00BSNM7G36.USD","IE00BFTCPJ56.SGD","LU0225284248.USD","IE00B2B36J28.USD","BK4532","LU2237443382.USD","KCE","BK4588","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111805047","title":"市场消息：阿斯利康与施贵宝之间没有就潜在交易进行任何讨论","url":"https://stock-news.laohu8.com/highlight/detail?id=1111805047","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111805047?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:09","pubTimestamp":1785931786,"startTime":"0","endTime":"0","summary":"8月5日，阿斯利康盘前涨超5%、施贵宝跌近3%；消息人士表示双方之间没有就潜在交易进行任何讨论。","market":"us","thumbnail":"https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"市场消息：阿斯利康与施贵宝之间没有就潜在交易进行任何讨论","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189670438","title":"异动解读｜阿斯利康盘前上涨4.77%，合并施贵宝传闻遭多方泼冷水后股价修复","url":"https://stock-news.laohu8.com/highlight/detail?id=1189670438","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189670438?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:05","pubTimestamp":1785931506,"startTime":"0","endTime":"0","summary":"8月5日，阿斯利康盘前上涨4.77%，报163.08美元/股，成交额2740.35万美元。消息面上，此前阿斯利康因洽谈合并百时美施贵宝的传闻股价大跌逾9%，但随后多家投行对该交易可行性表示质疑。BMO资本研报指出，两家公司均无足够财务实力直接收购对方，阿斯利康约可筹370亿美元，远低于4000亿美元合并所需资金。此外，阿斯利康与石药集团就成立合资公司签署合资合同，业务拓展信号积极。市场对巨型并购交易落地预期降温，前期超跌股价迎来修复。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康盘前上涨4.77%，合并施贵宝传闻遭多方泼冷水后股价修复","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657541044","title":"消息人士表示，阿斯利康(AZN.US)与施贵宝(BMY.US)之间没有就潜在交易进行任何讨论。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657541044","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657541044?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:04","pubTimestamp":1785931448,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BFXG1179.USD","LU0096364046.USD","LU1989771016.USD","FTXH","IE0009355771.USD","LU0432979614.USD","LU1670710661.SGD","LU1868836757.USD","AZN","LU2089984988.USD","BMY","LU0225771236.USD","IE00BSNM7G36.USD","LU0058720904.USD","LU0128525929.USD","LU2360032135.SGD","BK4007","LU1868837136.USD","LU0237698245.USD","IE00BFTCPJ56.SGD","AZNH","LU0889565916.HKD","LU1032466523.USD","LU1291159041.SGD","LU2237443549.SGD","LU1571399168.USD","LU2125154778.USD","LU2237443895.HKD","LU0306807586.USD","LU2133065610.SGD","LU0882574055.USD","LU0708994859.HKD","IHE","LU2237443465.HKD","LU0029864427.USD","LU1868837300.USD","LU2242646821.SGD","BK4585","IE00BJT1NW94.SGD","IE0002141913.USD","LU1829250122.USD","LU0985481810.HKD","LU2456880835.USD","LU1868836591.USD","LU2237443978.SGD","LU0114720955.EUR","LU2462157665.USD","LU2468319806.SGD","LU1670711040.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657027541","title":"一位知情资深消息人士称，阿斯利康与百时美施贵宝“从始至终从未有过交易谈判”。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657027541","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657027541?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:03","pubTimestamp":1785931439,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMY","LU1571399168.USD","LU0310800379.SGD","BK4534","LU0029864427.USD","IE00B3T34201.USD","LU1291159041.SGD","LU1261432733.SGD","LU1883839398.USD","LU2133065610.SGD","BK4568","LU0289739699.SGD","LU2237443382.USD","BK4559","LU1868836591.USD","LU0128525929.USD","LU0320765992.SGD","LU0985481810.HKD","LU0456855351.SGD","LU1670710661.SGD","AZNH","LU2237443978.SGD","LU1670711040.USD","LU1267930573.SGD","LU0708994859.HKD","LU2596442595.SGD","LU2089984988.USD","IE00B2B36J28.USD","LU1430594728.SGD","IE00BJJMRZ35.SGD","LU1829250122.USD","LU1032466523.USD","BK4581","IE00BFTCPJ56.SGD","BK4588","AZN","LU0225284248.USD","FTXH","LU0889565916.HKD","LU2462157665.USD","LU0321505868.SGD","LU2360032135.SGD","LU0267386448.USD","IHE","LU2456880835.USD","LU1093756168.USD","LU1093756325.SGD","LU1323610961.USD","LU1868836914.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657511043","title":"石药集团：与阿斯利康就成立合资公司签署合资合同。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657511043","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657511043?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:35","pubTimestamp":1785918905,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2468319806.SGD","BK4585","LU0029864427.USD","AZNH","IE00B3T34201.USD","LU2237443622.USD","LU0128525929.USD","LU2456880835.USD","LU0058720904.USD","AZN","LU2237443382.USD","LU2417539215.USD","LU0889565916.HKD","LU2237443978.SGD","LU0432979614.USD","LU1829250122.USD","LU2237443465.HKD","LU2089984988.USD","LU2462157665.USD","LU2237443549.SGD","BK4588","LU1267930573.SGD","LU0289739699.SGD","LU0109394709.USD","LU2236285917.USD","LU2237443895.HKD","BK4007","BK4568","LU0708994859.HKD","LU0310800379.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656080539","title":"阿斯利康拟与百时美施贵宝4000亿美元重组传闻背后：专利悬崖、产品短板倒逼，AZ端反对声大","url":"https://stock-news.laohu8.com/highlight/detail?id=2656080539","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656080539?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:26","pubTimestamp":1785835565,"startTime":"0","endTime":"0","summary":"蓝鲸新闻记者联系了阿斯利康方面，对方拒绝对此置评。此外，BMS有神经管线与Eliquis后续心血管资产，可补足AZ在相关领域的短板。据BMO资本在研报中指出，两家公司都没有足够的财务实力直接收购对方，预计阿斯利康能掏出约370亿美元，而百时美施贵宝约为320亿美元，远低于搞定一桩价值4000亿美元合并所需的资金。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1785835141389493693","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU0128525929.USD","LU1868836591.USD","LU2237443895.HKD","APXH","LU2242646821.SGD","AZNH","IYH","LU0432979614.USD","PPH","RSPH","FHLC","IHE","BMY","LU0321505868.SGD","LU1093756168.USD","LU1585245621.USD","LU2596442595.SGD","PBPH","BME","GSKH","BK4559","TMED","MEDI","LU2089984988.USD","LU0267386448.USD","LU2462157665.USD","LU1868836914.USD","LU1093756325.SGD","PJP","IE00BJJMRZ35.SGD","FTXH","LU0321505439.SGD","LU1868837300.USD","BBP","LU2237443382.USD","AZN","BBH","FXH","BK4588","IE00B2B36J28.USD","LU0882574055.USD","TRUH","JDOC","LU1670710588.SGD","LU1032466523.USD","LU1670711123.USD","AZ","LU0985481810.HKD","LU0225284248.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135442776","title":"美银：阿斯利康并购施贵宝逻辑存疑，监管与协同效应成焦点","url":"https://stock-news.laohu8.com/highlight/detail?id=1135442776","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135442776?lang=zh_cn&edition=full","pubTime":"2026-08-04 10:45","pubTimestamp":1785811514,"startTime":"0","endTime":"0","summary":"阿斯利康与施贵宝据悉正在就合并进行初步谈判，若交易最终达成，双方将组成全球规模最大的制药公司之一，并进一步强化在肿瘤药领域的市场地位。受相关消息影响，阿斯利康周一收跌6.8%，百时美施贵宝股价基本持平。两家公司本身均是肿瘤药领域的重要参与者。RBC Capital Markets分析师Trung Huynh认为，若双方合并，可能在免疫肿瘤、靶向疗法、抗体偶联药物以及血液肿瘤等热门研发方向形成更强组合。","market":"us","thumbnail":"https://community-static.tradeup.com/news/14189295ed36871c659485899fb4425b","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/14189295ed36871c659485899fb4425b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN","BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656585037","title":"RBC泼冷水：阿斯利康(AZN.US)收购百时美施贵宝(BMY.US)“可能性极低”，估值分歧与反垄断成最大拦路虎","url":"https://stock-news.laohu8.com/highlight/detail?id=2656585037","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656585037?lang=zh_cn&edition=full","pubTime":"2026-08-04 09:30","pubTimestamp":1785807028,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4559","AZN","IE0002141913.USD","AAPX","BK4532","LU1291159041.SGD","AAPY","LU1868836757.USD","LU1074936037.SGD","LU0432979614.USD","BK4585","APLY","AAPU","LU0321505868.SGD","LU1868836914.USD","LU0096364046.USD","LU2125154935.USD","LU1670711123.USD","LU1093756325.SGD","LU1983299246.USD","BK4007","LU2456880835.USD","LU1323610961.USD","AAPD","AAPW","LU2133065610.SGD","LU1989771016.USD","LU0882574055.USD","LU2417539215.USD","FTXH","LU0868494617.USD","AAPB","LU0128525929.USD","BMY","LU0306807586.USD","LU2468319806.SGD","AZNH","LU2237443382.USD","LU1829250122.USD","LU2236285917.USD","LU0225771236.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00BSNM7G36.USD","LU0456855351.SGD","IHE","LU1430594728.SGD","LU1267930573.SGD","LU0058720904.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656585753","title":"阿斯利康宣布创新药英卓凡正式在中国上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2656585753","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656585753?lang=zh_cn&edition=full","pubTime":"2026-08-04 09:20","pubTimestamp":1785806400,"startTime":"0","endTime":"0","summary":"南方财经8月4日电，阿斯利康宣布创新药物英卓凡?（英文商品名：Imjudo?，中文通用名：曲麦利尤单抗）正式在中国上市。今年4月，基于全球III期HIMALAYA研究及中国队列的积极结果，曲麦利尤单抗联合英飞凡?（中文通用名：度伐利尤单抗）在中国获批，用于晚期或不可切除的肝细胞癌（HCC）成人患者的一线治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608043830619273.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608043830619273.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MEDX","LU0109394709.USD","LU0432979614.USD","BK1161","LU0310800379.SGD","LU2462157665.USD","LU0128525929.USD","LU1829250122.USD","LU0289739699.SGD","IE00B3T34201.USD","BK4007","LU2236285917.USD","LU0320765992.SGD","LU2237443382.USD","LU2237443465.HKD","IBBQ","LU1267930573.SGD","LU2456880835.USD","LNGR","BK4585","LU2237443978.SGD","LU2468319806.SGD","BK4568","BK1574","LU0889565916.HKD","LU2417539215.USD","BK4588","LU2237443622.USD","LU2237443549.SGD","LU0708994859.HKD","LU2237443895.HKD","IPOS","LU0058720904.USD","159992","LU0029864427.USD","AZN","AZNH","LU2089984988.USD","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656303389","title":"阿斯利康投资者对巨型并购谈判表达担忧。","url":"https://stock-news.laohu8.com/highlight/detail?id=2656303389","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656303389?lang=zh_cn&edition=full","pubTime":"2026-08-04 00:29","pubTimestamp":1785774582,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["KCE","XMMO","IE00B3T34201.USD","LU2237443622.USD","LU0128525929.USD","LU0708994859.HKD","LU0058720904.USD","LU2462157665.USD","LU2237443978.SGD","LU0889565916.HKD","LU1267930573.SGD","LU2417539215.USD","LU0289739699.SGD","LU2237443465.HKD","LU2237443549.SGD","LU2237443382.USD","AZNH","BK4007","LU2236285917.USD","LU1829250122.USD","LU0109394709.USD","CALF","AZN","BK4585","MYLD","LU0029864427.USD","LU0320765992.SGD","BK4568","LU2089984988.USD","LU0432979614.USD","LU0310800379.SGD","LU2456880835.USD","LU2237443895.HKD","LU2468319806.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656370079","title":"阿斯利康伦敦股价收跌9%，创2020年3月份以来最大单日跌幅。","url":"https://stock-news.laohu8.com/highlight/detail?id=2656370079","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656370079?lang=zh_cn&edition=full","pubTime":"2026-08-03 23:38","pubTimestamp":1785771533,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AZN","BK4588","LU2236285917.USD","LU0708994859.HKD","LU1829250122.USD","LU0128525929.USD","LU1267930573.SGD","LU2417539215.USD","LU2237443978.SGD","LU0432979614.USD","LU0310800379.SGD","LU0058720904.USD","LU0889565916.HKD","LU0029864427.USD","LU0289739699.SGD","AZNH","LU2456880835.USD","LU2089984988.USD","BK4007","IE00B3T34201.USD","LU0109394709.USD","LU2237443622.USD","LU2468319806.SGD","LU2462157665.USD","LU2237443382.USD","LU0320765992.SGD","LU2237443465.HKD","LU2237443549.SGD","BK4585","LU2237443895.HKD","BK4568"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.0308},{"period":"1month","weight":-0.0708},{"period":"3month","weight":-0.1384},{"period":"6month","weight":-0.2389},{"period":"1year","weight":-0.0031},{"period":"ytd","weight":-0.1491}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.515152,"avgChangeRate":0.001662},{"month":2,"riseRate":0.424242,"avgChangeRate":-0.012868},{"month":3,"riseRate":0.545455,"avgChangeRate":0.025511},{"month":4,"riseRate":0.636364,"avgChangeRate":0.028791},{"month":5,"riseRate":0.515152,"avgChangeRate":0.008212},{"month":6,"riseRate":0.470588,"avgChangeRate":0.018421},{"month":7,"riseRate":0.588235,"avgChangeRate":-0.005538},{"month":8,"riseRate":0.470588,"avgChangeRate":0.002361},{"month":9,"riseRate":0.545455,"avgChangeRate":0.001232},{"month":10,"riseRate":0.545455,"avgChangeRate":0.015301},{"month":11,"riseRate":0.515152,"avgChangeRate":0.003764},{"month":12,"riseRate":0.545455,"avgChangeRate":0.007464}],"exchange":"NYSE","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}